文献速递头颈部肿瘤放疗中枢神经肿瘤放疗

鼻咽癌SIB-IMRT治疗前生存与晚期毒性预后因素

Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
PubMed 文献 · Radiat Oncol · 2018-03-20

该单中心回顾性研究纳入219例接受SIB-IMRT的非远处转移鼻咽癌患者,分析治疗前社会人口学、TNM分期、GTV、EBV-DNA及血液炎症标志物与生存和晚期毒性的关系。多因素分析显示N2-3分期是四项生存结局的唯一显著负性预后因素,GTV较大与较差LRRFS及更高放射性神经病变发生率相关。

要点

  • N2-3分期是全部四项生存结局的唯一显著负性预后因素。
  • 单核细胞百分比升高与较差FFS显著相关,淋巴细胞/单核细胞比值降低与较差OS显著相关。
  • GTV较大预测较差LRRFS,且T3-4或GTV较高与放射性神经病变发生率更高相关。

核心结论

  • 校正生物标志物后,N分期仍是SIB-IMRT治疗鼻咽癌最显著的生存预测因素。
  • GTV不仅影响局部区域控制,还与放射性神经病变相关。

研究设计与样本

  • 单中心连续纳入219例非远处转移鼻咽癌患者,均接受SIB-IMRT。
  • 分析治疗前社会人口学变量、TNM分期、GTV、EBV-DNA及血液炎症标志物。
  • 采用Cox模型筛选晚期毒性和四项生存结局的预后因素。

主要发现

  • 5年LRRFS、DMFS、FFS和OS率分别为87.9%、89.4%、79.4%和81.3%。
  • EBV-DNA、部分血液炎症标志物、GTV与N分类之间存在显著相互关联。
  • 多因素分析显示N2-3对比N0-1是全部四项生存结局的唯一显著负性预后因素。
  • 单核细胞百分比升高与较差FFS显著相关,淋巴细胞/单核细胞比值降低与较差OS显著相关。
  • GTV较大预测较差LRRFS;T3-4(HR: 3.5,95%CI: 1.0-12.1,p=0.048)或GTV较高(HR: 1.006,95%CI: 1.001-1.011,p=0.027)与放射性神经病变发生率更高相关。

临床怎么用

  • 治疗前应重点关注N分期,N2-3患者预后较差。
  • GTV较大者需关注局部区域控制及放射性神经病变风险。
  • 单核细胞百分比升高或淋巴细胞/单核细胞比值降低可能提示FFS或OS较差。

局限性

  • 单中心回顾性研究,样本量219例,结论需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To scrutinize the pretreatment prognosticators on survival and late toxicities in a homogenous cohort of nasopharyngeal carcinoma (NPC) patients treated by simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT). METHODS: A total of 219 non-distant metastatic NPC patients consecutively treated by SIB-IMRT at a single institute were collected. The pretreatment factors including the socio-demographic variables, TNM stages, gross tumor volume (GTV), Epstein-Barr virus (EBV)-DNA, and hematologic inflammatory markers were analyzed. Cox model was used to screen the prognostic factors of late toxicities and four survival outcomes including locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), failure-free survival (FFS), and overall survival (OS). RESULTS: Statistically significant inter-correlations were observed between the values of EBV-DNA, some hematologic inflammatory markers, GTV, and N classification. The 5-year LRRFS, DMFS, FFS, and OS rates were 87.9%, 89.4%, 79.4%, and 81.3%, respectively. Multivariate analysis revealed that advanced N classification (N2-3 vs. N0-1) remained the only significant negative prognosticator for all the four survival outcomes. An increased monocyte percentage and a decreased lymphocyte-to-monocyte ratio were significantly associated with poorer FFS and OS, respectively. Larger GTV was observed to be predictive of poorer LRRFS. Patients with T3-4 (HR: 3.5, 95% CI: 1.0-12.1, p = 0.048) or higher GTV (HR: 1.006, 95% CI: 1.001-1.011, p = 0.027) were associated with higher incidence of radiation neuropathy. CONCLUSION: N classification remains the most significant survival predictor for NPC patients treated by SIB-IMRT after adjusting these biomarkers. GTV impacts not only on locoregional control but also radiation neuropathy.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lin YH, Huang TL, Chien CY, et al. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy. Radiat Oncol. 2018. PMID: 29554940. doi:10.1186/s13014-018-0990-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。